Cell MedX Corp. Engages Nutrasource Diagnostics Inc. to Commence Clinical Trials in Canada

Cell MedX Corp. (OTCQB:CMXC) announced that it has engaged Nutrasource Diagnostics Inc. (“NDI”) to commence clinical trials of its innovative and proprietary technology branded under the trade name eBalance. The intent of the upcoming trial is to assess and quantify eBalance’s ability to alter key metabolic pathways targeting improved blood sugar control. The trial will be conducted at several sites across Canada, after review and approval from Health Canada and a central Research Ethics Board (REB).
According to the news:

NDI’s clinical and medical teams will work, in collaboration with physicians, to treat and monitor patients several times per week according to the protocols developed by Cell MedX. The end points in the study include:
1) reduction in HbA1c levels;
2) improvement in insulin sensitivity and a reduction in insulin resistance;
– Increased Sensitivity — patients using insulin injections examine the increase of sensitivity while using less insulin for the same food intake.
– Reduction in insulin resistance — in Type 1 Diabetes patients (this would fall under insulin sensitivity). In type Two Diabetes patients — verify improvement with insulin resistance through reduction in medication.
3) improvement in complications directly related to diabetes;
– Diabetic neuropathy
– Acceleration in wound healing
– Improvement in blood pressure control

Cell MedX President and CEO, Mr. Frank McEnulty, commented:

We are very excited to engage Nutrasource to conduct clinical trials for us in Canada, as our ongoing observational studies have shown that our eBalance technology has had positive effect on pain management as well as complications associated with diabetes.

Click here to view the full press release.